| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Gastrointestinal Stent Market Size 2024 |
USD 546.52 Million |
| Gastrointestinal Stent Market, CAGR |
5.10% |
| Gastrointestinal Stent Market Size 2032 |
USD 813.63 Million |
Market Overview
The gastrointestinal stent market is projected to witness substantial growth, with its value expected to surge from USD 546.52 million in 2024 to USD 813.63 million by 2032, representing a compound annual growth rate of 5.10%.
The gastrointestinal stent market is being propelled by several key drivers and trends. Increasing prevalence of gastrointestinal disorders, such as colorectal cancer and inflammatory bowel disease, is stimulating demand for minimally invasive treatment options like stent placement. Technological advancements in stent design, such as the development of self-expandable metallic stents (SEMS) and biodegradable stents, are enhancing treatment efficacy and patient outcomes. Moreover, rising geriatric population prone to gastrointestinal ailments and growing adoption of endoscopic procedures are further augmenting market growth. Additionally, expanding healthcare infrastructure and growing awareness about minimally invasive treatment alternatives are facilitating market expansion across diverse geographic regions.
In the geographical analysis of the gastrointestinal stent market, North America holds a significant share, driven by factors like high healthcare expenditure, advanced healthcare infrastructure, and a large patient pool. Europe follows suit, propelled by the increasing prevalence of gastrointestinal disorders and favorable reimbursement policies. The Asia-Pacific region is anticipated to witness rapid growth, attributed to rising healthcare expenditure, growing awareness about minimally invasive procedures, and expanding access to healthcare facilities. Key players in the gastrointestinal stent market include Boston Scientific Corporation, Cook Medical LLC, C.R. Bard, Inc. (BD), and Olympus Corporation, among others, who are actively engaged in product development and strategic collaborations to maintain their competitive edge in the market.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Drivers
Rising Prevalence of GI Disorders:
Increased diagnoses of gastrointestinal diseases have been observed globally, driven by factors such as improved diagnostic tools, aging populations, and lifestyle changes. For instance, it is estimated that in the United States, 11% of the population suffer from a chronic digestive disease, with a prevalence rate as high as 35% for those 65 years and over. Conditions like esophageal cancer, colorectal cancer, and inflammatory bowel disease (IBD) are becoming more prevalent. Each year 62 million Americans are diagnosed with a digestive disorder. As these diagnoses rise, there is a corresponding increase in demand for minimally invasive treatment options like stents. Public health initiatives and media attention are also contributing to growing awareness of GI symptoms and diseases, leading to earlier diagnoses and heightened patient demand for treatment options like stents.
Technological Advancements in Stent Design:
Manufacturers are continually innovating by developing new and improved stents with better materials, self-expanding mechanisms, and drug-eluting properties. For instance, the advancements offer improved efficacy, with drug-eluting stents showing a reduction in the risk of restenosis by 50-70% compared to bare-metal stents. Patient comfort is also enhanced, as the newer generation of stents requires shorter periods of dual antiplatelet therapy, reducing the duration from 12 months to as little as 3 months in some cases. Moreover, the trend towards minimally invasive surgical procedures for GI issues is a significant driver. Stents provide a less invasive alternative to traditional surgery for treating blockages and strictures in the GI tract, with the success rate of endoscopic stent placement being over 90%, and the procedure time can be as short as 30-60 minutes.
Demographic Factors:
The global population is indeed aging, with significant implications for healthcare. For instance, by 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%. This demographic shift creates a larger patient pool for GI stent procedures, as older adults are more susceptible to GI disorders, affecting over a third of people aged 65+. Additionally, rising disposable incomes in many parts of the world enable patients to access advanced medical treatments like stents. For example, with an increase in income, the disposable income also rises, which raises health consciousness and ultimately the spending on healthcare. This economic factor further drives the growth of the market for medical treatments such as GI stents.
Other Supporting Factors:
Favorable reimbursement policies from governments that reimburse hospitals and healthcare providers for stent procedures can stimulate market growth. Moreover, there is a strong focus on improving patient outcomes, as stents offer faster recovery times and reduced complications compared to traditional surgeries. This makes them an attractive option for both patients and healthcare providers alike, further fueling market expansion.
Market Trends
Focus on Biodegradable Stents:
Traditional stents often necessitate a secondary procedure for removal, posing inconvenience and additional healthcare costs to patients. For instance, the cost of DJ stent removal procedures in India can range from ₹12,000 to ₹20,000, and the treatment duration is typically 15 to 20 minutes. Biodegradable stents, crafted from absorbable materials, dissolve naturally within the body after fulfilling their intended purpose. This eradicates the need for another procedure, significantly enhancing patient comfort and reducing healthcare expenses. The benefits of biodegradable stents include good biocompatibility, better mechanical properties than currently used polyurethane stents, and the capability to mitigate surface crusting. Additionally, they have the potential to deliver more drugs to the target site than a thin coating of drug on metallic stents, further enhancing their therapeutic efficacy.
Innovative Stent Designs:
Self-expanding and self-navigating stents represent a paradigm shift in gastrointestinal stent technology. Emerging stents are engineered to self-expand to the appropriate diameter once positioned in the GI tract, streamlining the insertion process. Furthermore, some stents are incorporating self-navigation features, facilitating easier and more precise placement during endoscopic procedures. Drug-eluting stents equipped with targeted drug delivery mechanisms are revolutionizing treatment approaches. These advanced stents have the capability to administer medication directly to the affected area in the GI tract, thereby enhancing treatment efficacy and minimizing the risk of systemic side effects associated with oral medications. For example, recent advancements in stent design aim to decrease the risk of stent thrombosis while allowing shorter duration of dual antiplatelet therapy (DAPT) in patients at high bleeding risk.
Market Challenges Analysis
Complications and Risks of Stent Procedures:
GI stent placement, although a common medical procedure, is not without risks. Potential complications include stent migration, tissue overgrowth, bleeding, and perforation of the GI tract. These complications may necessitate additional procedures, leading to increased healthcare costs and patient discomfort. Managing these risks effectively is crucial for ensuring successful outcomes and patient safety. The high cost associated with GI stents and the procedures involved poses a significant challenge, particularly for patients in regions with limited healthcare budgets or underdeveloped insurance systems. The affordability of stents and related procedures can impact accessibility, potentially limiting treatment options for some patients. Addressing cost barriers is essential for ensuring equitable access to gastrointestinal care across diverse populations.
Regulatory and Technological Hurdles:
Stringent regulatory requirements governing medical devices, including GI stents, present challenges for manufacturers seeking approval for new designs. Navigating the regulatory landscape can be a time-consuming and costly process, potentially delaying the availability of innovative stent technologies to patients. Overcoming these regulatory hurdles requires robust compliance strategies and close collaboration with regulatory authorities to ensure timely market access for new products. Another challenge is the lack of long-term data on the efficacy and safety of newer stent technologies, such as biodegradable stents and drug-eluting stents. Healthcare providers may be hesitant to adopt these innovative options without sufficient evidence of their long-term benefits and potential risks. Generating comprehensive clinical data and conducting rigorous post-market surveillance are essential for addressing these concerns and building confidence in novel stent technologies among clinicians and patients alike.
Market Segmentation Analysis:
By Products:
The gastrointestinal stent market is segmented by products, reflecting the diverse range of stent types catering to specific gastrointestinal conditions. Biliary stents are utilized for treating obstructions in the bile ducts, commonly caused by conditions like gallstones or cancer. Duodenal stents are designed to alleviate blockages in the duodenum, often resulting from tumors or strictures. Colonic stents are employed in the treatment of colorectal obstructions, offering a minimally invasive alternative to surgery. Pancreatic stents are utilized to manage strictures or blockages in the pancreatic duct, commonly associated with pancreatic cancer or chronic pancreatitis. Esophageal stents are used to relieve dysphagia caused by esophageal strictures, typically arising from conditions like esophageal cancer or gastroesophageal reflux disease (GERD). By catering to specific anatomical locations and conditions within the gastrointestinal tract, these stent products address diverse patient needs and contribute to the comprehensive management of gastrointestinal disorders.
By Material:
The gastrointestinal stent market is further segmented based on material composition, reflecting the technological diversity and evolving materials used in stent manufacturing. Self-expanding metal stents (SEMS) are characterized by their ability to expand upon deployment, providing immediate relief to obstructed areas within the gastrointestinal tract. Nitinol stents, crafted from a nickel-titanium alloy, offer flexibility and resilience, making them suitable for navigating tortuous anatomical pathways. Stainless steel stents are known for their durability and strength, providing long-term support in challenging anatomical conditions. Other metal stents encompass a variety of materials, including alloys tailored to specific clinical requirements. Plastic stents, composed of biocompatible polymers, offer flexibility and ease of deployment, particularly in endoscopic procedures. By leveraging diverse materials, gastrointestinal stent manufacturers can optimize performance characteristics and tailor stents to meet the unique needs of patients with various gastrointestinal conditions.
Segments:
Based on Products
- Biliary stents
- Duodenal stents
- Colonic stents
- Pancreatic stents
- Esophageal stents
Based on Material
- Self-expanding metal stents
- Nitinol
- Stainless steel
- Other metal stents
- Plastic stents
Based on Application
- Biliary diseases
- Irritable bowel syndrome
- Gastrointestinal cancers
- Colorectal cancer
- Stomach cancer
- Esophageal cancer
- Pancreatic cancer
Based on End Users
- Hospitals and Clinics
- Ambulatory Surgical Centers
Based on the Geography
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis
North America
North America currently holds the largest market share, accounting for approximately 35% of the global gastrointestinal stent market. The region’s well-established healthcare infrastructure, the presence of major industry players, and the high adoption rate of advanced medical technologies have contributed to its dominant position. The United States, in particular, has been at the forefront of adopting innovative gastrointestinal stents for the treatment of conditions such as esophageal cancer, colorectal cancer, and gastrointestinal obstructions.
Europe
Europe follows closely behind, with a market share of around 30%. Countries like Germany, France, and the United Kingdom have been proactive in promoting early detection and effective management of gastrointestinal diseases. The region’s focus on improving patient outcomes, reducing healthcare costs associated with invasive surgical procedures, and the availability of advanced gastrointestinal stents have fueled market growth. Additionally, the increasing geriatric population and the rising incidence of gastrointestinal disorders have further boosted the demand for reliable stenting solutions in Europe.
Key Player Analysis
- Boston Scientific Corporation
- Cantel Medical
- Conmed Corporation
- Cook Medical
- ELLA-CS, s.r.o.
- Gore Medical
- Hobbs Medical
- Medtronic plc,
- Micro-Tech (Nanjing) Co
- Olympus America
Competitive Analysis
In the competitive landscape of the gastrointestinal stent market, leading players such as Boston Scientific Corporation, Cook Medical, and Medtronic plc dominate with their extensive product portfolios and global presence. Boston Scientific Corporation is renowned for its innovative stent designs, particularly in the field of self-expanding metal stents (SEMS), offering advanced solutions for various gastrointestinal conditions. Cook Medical excels in providing a wide range of stent options, including plastic and metal stents, catering to diverse patient needs. Medtronic plc leverages its expertise in medical devices to deliver high-quality stent solutions, focusing on enhancing patient outcomes and procedural efficiency. Other notable players like Cantel Medical, Conmed Corporation, and Olympus America also contribute significantly to the market with their innovative stent offerings and commitment to advancing gastrointestinal care. With continuous innovation, strategic partnerships, and a focus on addressing unmet clinical needs, these leading players remain pivotal in driving the growth and competitiveness of the gastrointestinal stent market.
Recent Developments
In February 2023, Olympus Corporation announced the acquisition of Taewoong Medical Co., Ltd, a manufacturer of medical devices including gastrointestinal (GI) metallic stents among others. This acquisition helped the company to expand their GI EndoTherapy product portfolio, enhance their R&D capabilities and increase the business revenue.
In June 2022, Boston Scientific Corporation announced a strategic agreement with Synergy Innovation Co., Ltd to acquire a majority shares of M.I.Tech Co., Ltd. This company is a manufacturer of HANAROSTENT technology, providing conformable, non-vascular, self-expanding metal stents. This strategic move helped the company to integrate advance technologies in their business, enhance their customer base and gain a competitive edge over its peers.
Market Concentration & Characteristics
The gastrointestinal stent market exhibits characteristics of moderate to high market concentration, with a few key players dominating a significant share of the market. Leading companies such as Boston Scientific Corporation, Cook Medical, and Medtronic plc command substantial influence due to their extensive product portfolios, global distribution networks, and strong brand recognition. This concentration is primarily driven by factors such as technological expertise, regulatory compliance capabilities, and strategic investments in research and development. Additionally, the market is characterized by ongoing innovations in stent design, materials, and delivery systems, aimed at improving patient outcomes and procedural efficiency. Despite the competitive landscape, entry barriers such as stringent regulatory requirements and the need for substantial investment in research and development pose challenges for new entrants. Overall, market concentration in the gastrointestinal stent market underscores the importance of strategic collaborations, product differentiation, and market expansion initiatives for sustained growth and competitiveness.
Report Coverage
The research report offers an in-depth analysis based on Products, Material, Application, End Users, and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Future Outlook
- Continued Technological Advancements: Future innovations in stent design and materials are anticipated, enhancing efficacy and patient comfort.
- Rising Demand for Minimally Invasive Procedures: Increasing preference for less invasive treatment options is expected to drive market growth.
- Expansion of Indications: Stents may find application in new indications within the gastrointestinal tract, broadening their market potential.
- Personalized Medicine: Customized stent designs based on patient-specific anatomy and conditions could become more prevalent.
- Integration of Robotics and AI: Adoption of robotics and artificial intelligence is likely to improve procedural precision and patient outcomes.
- Focus on Biodegradable Stents: Development of biodegradable stents may reduce the need for secondary removal procedures, enhancing patient comfort and reducing costs.
- Remote Monitoring Technologies: Stents with embedded sensors may enable remote monitoring of patient recovery and stent performance, leading to more personalized care.
- Emerging Markets: Growing healthcare infrastructure and increasing disposable incomes in emerging economies may drive market expansion.
- Regulatory Landscape: Continued adherence to stringent regulatory requirements will be crucial for ensuring patient safety and product quality.
- Competition from Alternative Treatments: The market may face competition from alternative treatments such as minimally invasive surgical techniques, requiring ongoing innovation and differentiation to maintain market share.
